The Hadassah-University Medical Centre has made a groundbreaking advancement in the treatment of multiple myeloma, the second most common hematological cancer. Their CAR-T therapy has emerged as a highly effective method with an exceptional success rate of over 90%.
The innovative process involves extracting T-cells from the patient’s healthy white blood cells, which are integral to the immune system. These T-cells are then genetically modified and reintroduced into the patient’s body. The modified T-cells are programmed to specifically target and eliminate cancer cells, providing a highly targeted and personalized approach to treatment.
Excitingly, IMMX Bio has obtained a patent license for this cutting-edge technology. They are now set to launch a clinical trial in the United States, with the ultimate goal of obtaining commercialization and FDA approval as a drug within a year. This development signifies a significant step forward in the field of cancer treatment, offering new hope to patients battling multiple myeloma.
The groundbreaking CAR-T therapy developed by Hadassah-University Medical Centre demonstrates the power of innovation and research in advancing medical treatments. With its impressive success rate and the prospect of further development and approval, this therapy has the potential to transform the lives of individuals affected by multiple myeloma.
